The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Therapeutic Potential of Mesenchymal Stem Cells in Regenerative Medicine
Open accessAbstract
Mesenchymal stem cells (MSCs) are stromal cells that have the ability to self-renew and also exhibit multilineage differentiation into both mesenchymal and nonmesenchymal lineages. The intrinsic properties of these cells make them an attractive candidate for clinical applications. MSCs are of keen interest because they can be isolated from a small aspirate of bone marrow or adipose tissues and can be easily expanded in vitro. Moreover, their ability to modulate immune responses makes them an even more attractive candidate for regenerative medicine as allogeneic transplant of these cells is feasible without a substantial risk of immune rejection. MSCs secrete various immunomodulatory molecules which provide a regenerative microenvironment for a variety of injured tissues or organ to limit the damage and to increase self-regulated tissue regeneration. Autologous/allogeneic MSCs delivered via the bloodstream augment the titers of MSCs that are drawn to sites of tissue injury and can accelerate the tissue repair process. MSCs are currently being tested for their potential use in cell and gene therapy for a number of human debilitating diseases and genetic disorders. This paper summarizes the current clinical and nonclinical data for the use of MSCs in tissue repair and potential therapeutic role in various diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Le Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734
Canonical WNT Signaling Promotes Osteogenesis by Directly Stimulating Runx2 Gene Expression
Gaur, T., Lengner, C. J., Hovhannisyan, H., Bhat, R. A., Bodine, P. V. N., Komm, B. S., Javed, A., van Wijnen, A. J., Stein, J. L., Stein, G. S., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500608200 · Cited by 1,170
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals
Djouad, F., Plence, P., Bony, C., Tropel, P., Apparailly, F., Sany, J., Noël, D., & Jorgensen, C. (2003) · Blood · doi:10.1182/blood-2003-04-1193 · Cited by 1,166 · cited 2×
“Moreover, MSCs can induce development of CD8 regulatory T (Treg) cells than can in turn successfully suppress allogeneic lymphocyte responses [56] and prohibit differentiation of monocytes and CD34 progenitors into antigen presenting dendritic cells [57].”
BackgroundInteractions Between Human Mesenchymal Stem Cells and Natural Killer Cells
Sotiropoulou, P. A., Perez, S. A., Gritzapis, A. D., Baxevanis, C. N., & Papamichail, M. (2006) · Stem Cells · doi:10.1634/stemcells.2004-0359 · Cited by 956 · cited 1×
“MSCs are also capable of inhibiting the proliferation of IL-2 or IL-15 stimulated NK cells [59, 60].”
BackgroundIn vitro Hepatic Differentiation of Human Mesenchymal Stem Cells
Lee, K., Kuo, T. K., Whang–Peng, J., Chung, Y., Lin, C., Chou, S., Chen, J., Chen, Y., & Lee, O. K. (2004) · Hepatology · doi:10.1002/hep.20469 · Cited by 865
Immunosuppressive properties of mesenchymal stem cells: advances and applications
P. De Miguel, M., Fuentes-Julian, S., Blazquez-Martinez, A., Y. Pascual, C., A. Aller, M., Arias, J., & Arnalich-Montiel, F. (2012) · Current Molecular Medicine · doi:10.2174/156652412800619950 · Cited by 660
Duijvestein, M., Vos, A. C. W., Roelofs, H., Wildenberg, M. E., Wendrich, B. B., Verspaget, H. W., Kooy-Winkelaar, E. M. C., Koning, F., Zwaginga, J. J., Fidder, H. H., et al. (2010) · Gut · doi:10.1136/gut.2010.215152 · Cited by 622 · cited 1×
“Therapeutic benefits of MSCs have also been hinted for Crohn’s disease [157]; however, large scale clinical studies are required to obtain concrete results.”
BackgroundMarcacci, M., Kon, E., Moukhachev, V., Lavroukov, A., Kutepov, S., Quarto, R., Mastrogiacomo, M., & Cancedda, R. (2007) · Tissue Engineering · doi:10.1089/ten.2006.0271 · Cited by 589 · cited 1×
“In vitro expandedMSCs loaded on porous hydroxyapatite scaffolds were used to cure bone nonunion and diaphyseal defects which resulted in good integration of implant [140, 141].”
MethodKharaziha, P., Hellström, P. M., Noorinayer, B., Farzaneh, F., Aghajani, K., Jafari, F., Telkabadi, M., Atashi, A., Honardoost, M., Zali, M. R., et al. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832a1f6c · Cited by 492 · cited 1×
“[123] P.”
Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer
Loebinger, M. R., Eddaoudi, A., Davies, D., & Janes, S. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4698 · Cited by 417
Zhang, Z., Lin, H., Shi, M., Xu, R., Fu, J., Lv, J., Chen, L., Lv, S., Li, Y., Yu, S., et al. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07024.x · Cited by 372 · cited 1×
“Umbilical cord -MSC therapy also significantly improved liver function, as indicated by the increase of serum albumin levels, decrease in total serum bilirubin levels, and decrease in theMELD scores during one-year follow-up studies [125].”
BackgroundImaging tri-fusion multimodality reporter gene expression in living subjects
Ray, P., De, A., Min, J.-J., Tsien, R. Y., & Gambhir, S. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1816 · Cited by 329
Macrophages modulate the viability and growth of human mesenchymal stem cells
Freytes, D. O., Kang, J. W., Marcos‐Campos, I., & Vunjak‐Novakovic, G. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24357 · Cited by 255 · cited 1×
“Anti-inflammatory environment is more accommodating to the therapeutic hMSCs than a proinflammatory environment [47].”
BackgroundEl-Ansary, M., Abdel-Aziz, I., Mogawer, S., Abdel-Hamid, S., Hammam, O., Teaema, S., & Wahdan, M. (2012) · Stem Cell Reviews and Reports · doi:10.1007/s12015-011-9322-y · Cited by 179
Targeted Delivery of CX3CL1 to Multiple Lung Tumors by Mesenchymal Stem Cells
Xin, H., Kanehira, M., Mizuguchi, H., Hayakawa, T., Kikuchi, T., Nukiwa, T., & Saijo, Y. (2007) · STEM CELLS · doi:10.1634/stemcells.2006-0461 · Cited by 164 · cited 2×
“[183] H.”
BackgroundPotential implications of mesenchymal stem cells in cancer therapy
Dai, L.-J., Moniri, M. R., Zeng, Z.-R., Zhou, J. X., Rayat, J., & Warnock, G. L. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.02.012 · Cited by 99
Cited by
Bacakova, L., Zarubova, J., Travnickova, M., Musilkova, J., Pajorova, J., Slepicka, P., Kasalkova, N. S., Svorcik, V., Kolska, Z., Motarjemi, H., et al. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.03.011 · Cited by 647
Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review
Margiana, R., Markov, A., Zekiy, A. O., Hamza, M. U., Al-Dabbagh, K. A., Al-Zubaidi, S. H., Hameed, N. M., Ahmad, I., Sivaraman, R., Kzar, H. H., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03054-0 · Cited by 429
Regenerative abilities of mesenchymal stem cells through mitochondrial transfer
Paliwal, S., Chaudhuri, R., Agrawal, A., & Mohanty, S. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0429-1 · Cited by 334
El Omar, R., Beroud, J., Stoltz, J.-F., Menu, P., Velot, E., & Decot, V. (2014) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2013.0664 · Cited by 330
Mesenchymal Stem/Stromal Cell Senescence: Hallmarks, Mechanisms, and Combating Strategies
Weng, Z., Wang, Y., Ouchi, T., Liu, H., Qiao, X., Wu, C., Zhao, Z., Li, L., & Li, B. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac004 · Cited by 285
Metadata
- Authors
- Patel, D. M., Shah, J., & Srivastava, A. S.
- Venue
- Stem Cells International
- Publisher
- Hindawi Limited
- Published
- 2013
- Volume
- 2013
- Pages
- 1-15
- ISSN
- 1687-966X (ISSN-L)
- 1687-9678
- OpenAlex
- W2069724639
- Cited by
- 247
- References
- 17
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.